Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

Autor: Sharon Love, Pippa Corrie, S B Mohammed, V. Urbonas, M Goff, Claire Scudder, Matthew Wheater, Dirk Schadendorf, Elizabeth Ruth Plummer, Cornelia Mauch, Lisa Zimmer, Mark R. Middleton, Ernie Marshall, Sarah Danson

Publikováno v: Annals of Oncology

Background Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the mitogen-activated protein kinase pathway is activated in most melanoma, includi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::693c356d08bf1e1bf51c5f631c6e1644
http://europepmc.org/articles/PMC6386028

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Autor: Patrick Julier, David N. Church, Eva Segelov, Francesco Pezzella, Enric Domingo, Peter J. Hewett, Ian Tomlinson, David J. Kerr, Elaine C. Johnstone, Beverly L. Falcon, Sharon Love, Sarah Pearson, Andrew Weaver, Rachel Kerr, Claire Scudder

Publikováno v: Lancet Oncology. 17(11)

Background Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc91905ae351438ef871a3b0e4a36539
http://ora.ox.ac.uk/objects/uuid:

Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma

Autor: Sharon Love, S B Mohammed, Ernie Marshall, Claire Scudder, Dirk Schadendorf, Mark R. Middleton, Sarah Danson, M Goff, Pippa Corrie

Publikováno v: Cancer Research. 77:CT123-CT123

Background: The aim of this open label study was to assess the efficacy of paclitaxel alone compared with paclitaxel in combination with either the MEK inhibitor trametinib or the anti-angiogenic agent pazopanib in metastatic melanoma. Methods: Eligi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a0cf4654df6ab71826959175bf1a426
https://doi.org/10.1158/1538-7445.am2017-ct123

Capecitabine (CAPE) +/- Bevacizumab (BEV) in the Adjuvant Treatment of Colorectal Cancer (CRC) - First and Final Toxicity Results from the International Phase III QUASAR2 Trial

Autor: David R. Ferry, Claire Scudder, Andrew Weaver, Patrick Julier, Simon Aird Grumett, David J. Kerr, Sharon Love, Eva Segelov, Rachel Midgley, Vanessa Potter

Publikováno v: Annals of Oncology. 23:ix181-ix182

Background Bevacizumab is an anti-VEGF antibody approved for use in metastatic colorectal cancer (CRC). However 2 trials have suggested lack of efficacy in combination with dual agent chemotherapy in the adjuvant setting and there has been some indic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8711b456380fd5d0d8c8ec65220b52e4
https://doi.org/10.1016/s0923-7534(20)33108-2

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Autor: Rosmarin D; Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Ian Tomlinson, Wellcome Trust Centre for Human Genetics, NIHR Comprehensive Biomedical Research Centre, University of Oxford; Dan Rosmarin, David Church, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Rachel Midgley, David Kerr, and George Nicholson, University of Oxford, Oxford; Michael Braun, The Christie NHS Foundation Trust, Manchester; Matthew Seymour, St James's University Hospital, Leeds; Lindsay Thompson, Medical Research Council Clinical Trials Unit; Rohini Sharma, Imperial College Healthcare NHS Trust, Hammersmith and Charing Cross Hospitals, London, United Kingdom; Anna Gonzalez-Neira, Spanish National Cancer Research Centre; Miguel Martin, Instituto de Investigacion Sanitaria Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid; Nuria Ribelles, Hospital Universitario Virgen de la Victoria, Málaga; Eva Martinez-Balibrea, Institut Català d'Oncologia, Institut de Recerca Sanitària Germans Trias i Pujol, Barcelona; Jesus Garcia-Foncillas, University Clinic of Navarra, University of Navarra, Pamplona, Spain; Daniel Sargent, Erin Green, Mayo Clinic, Rochester, MN; Howard McLeod, University of North Carolina, Chapel Hill, NC; Ulrich M. Zanger, Matthias Schwab, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart; Ulrich M. Zanger, Matthias Schwab, University Hospital Tuebingenl, Tuebingen, Germany; Benjamin Lacas, Valérie Boige, Jean-Pierre Pignon, Institut Gustave Roussy, Villejuif; Marie-Christine Etienne-Grimaldi, Gérard Milano, Centre Antoine Lacassagne, Nice; Thierry Lecomte, Pierre Laurent-Puig, Assistance Publique Hopitaux de Paris, Hopital Européen Georges Pompidou, Paris; Alain Morel, Institut National de la Sante et de la Recherche Medicale U564, Centre Paul Papin, Angers, France; Shoaib Afzal, Henrik Enghusen, Laboratory of Clinical Pharmacology, Rigshospitalet, Copenhagen; Sør, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Apr 01; Vol. 32 (10), pp. 1031-9. Date of Electronic Publication: 2014 Mar 03.